fenofibrate has been researched along with Hepatocellular Carcinoma in 12 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus BGL003 should be safe and suitable strategy to endow hydrophobic molecules with much hydrophilicity." | 5.38 | Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells. ( Hattori, H; Ishizawa, K; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Tsuchiya, K; Watanabe, M, 2012) |
| " Thus BGL003 should be safe and suitable strategy to endow hydrophobic molecules with much hydrophilicity." | 1.38 | Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells. ( Hattori, H; Ishizawa, K; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Tsuchiya, K; Watanabe, M, 2012) |
| " The dose-response for one or more key event(s) linked to the MOA for carcinogenicity allows a point of departure (POD) to be selected from the most sensitive effect dose or no-effect dose." | 1.36 | Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. ( Baker, TK; Bercu, JP; Flagella, KM; Jolly, RA; Romero, P; Stevens, JL, 2010) |
| "Fenofibrate-treated mice exhibited increases in AMPK phosphorylation and a decrease in PEPCK expression in the liver but not in skeletal muscles, suggesting that unmetabolized fenofibrate accumulated and affected AMPK only in the liver." | 1.36 | Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes. ( Cheng, XW; Kataoka, H; Murakami, H; Murakami, R; Murohara, T; Numaguchi, Y; Okumura, K; Takahashi, R, 2010) |
| "Fenofibrate treatment preserved AdipoR2 and phosphorylated AMPK (pAMPK) levels in palmitate-treated cells accompanied by reduced triglyceride (TG) accumulation and less activation of ER stress markers CCAAT/enhancer binding (C/EBPbeta) and eukaryotic translation initiation factor 2 alpha." | 1.35 | Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. ( Friedman, JE; Janssen, RC; Qadri, I; Rahman, SM, 2009) |
| " The results suggest that, although long-term administration of PPs causes liver cancer in susceptible species (e." | 1.31 | Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. ( Jiao, HL; Zhao, BL, 2002) |
| "Fenofibrate was compared to clofibrate to investigate whether their relative effects on lipoprotein production in Hep G2 cells were comparable to their relative effects on plasma lipoproteins." | 1.28 | Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. ( Goldberg, DM; Hahn, SE, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hata, K | 1 |
| Sayaka, T | 1 |
| Takahashi, M | 1 |
| Sasaki, A | 1 |
| Umekawa, Y | 1 |
| Miyashita, K | 1 |
| Ogura, K | 1 |
| Toshima, G | 1 |
| Maeda, M | 1 |
| Takahashi, J | 1 |
| Kakuni, M | 1 |
| You, BJ | 1 |
| Hour, MJ | 1 |
| Chen, LY | 1 |
| Luo, SC | 1 |
| Hsu, PH | 1 |
| Lee, HZ | 1 |
| Rahman, SM | 1 |
| Qadri, I | 1 |
| Janssen, RC | 1 |
| Friedman, JE | 1 |
| Chanda, D | 1 |
| Lee, CH | 1 |
| Kim, YH | 1 |
| Noh, JR | 1 |
| Kim, DK | 1 |
| Park, JH | 1 |
| Hwang, JH | 1 |
| Lee, MR | 1 |
| Jeong, KH | 1 |
| Lee, IK | 1 |
| Kweon, GR | 1 |
| Shong, M | 1 |
| Oh, GT | 1 |
| Chiang, JY | 1 |
| Choi, HS | 1 |
| Bercu, JP | 1 |
| Jolly, RA | 1 |
| Flagella, KM | 1 |
| Baker, TK | 1 |
| Romero, P | 1 |
| Stevens, JL | 1 |
| Murakami, R | 1 |
| Murakami, H | 1 |
| Kataoka, H | 1 |
| Cheng, XW | 1 |
| Takahashi, R | 1 |
| Numaguchi, Y | 1 |
| Murohara, T | 1 |
| Okumura, K | 1 |
| Yamasaki, D | 1 |
| Kawabe, N | 1 |
| Nakamura, H | 1 |
| Tachibana, K | 1 |
| Ishimoto, K | 1 |
| Tanaka, T | 1 |
| Aburatani, H | 1 |
| Sakai, J | 1 |
| Hamakubo, T | 1 |
| Kodama, T | 1 |
| Doi, T | 1 |
| Miyamoto, L | 1 |
| Watanabe, M | 1 |
| Kono, M | 1 |
| Matsushita, T | 1 |
| Hattori, H | 1 |
| Ishizawa, K | 1 |
| Nemoto, H | 1 |
| Tsuchiya, K | 1 |
| Jiao, HL | 1 |
| Zhao, BL | 1 |
| Dharancy, S | 1 |
| Malapel, M | 1 |
| Perlemuter, G | 1 |
| Roskams, T | 1 |
| Cheng, Y | 1 |
| Dubuquoy, L | 1 |
| Podevin, P | 1 |
| Conti, F | 1 |
| Canva, V | 1 |
| Philippe, D | 1 |
| Gambiez, L | 1 |
| Mathurin, P | 1 |
| Paris, JC | 1 |
| Schoonjans, K | 1 |
| Calmus, Y | 1 |
| Pol, S | 1 |
| Auwerx, J | 1 |
| Desreumaux, P | 1 |
| Clavey, V | 1 |
| Copin, C | 1 |
| Mariotte, MC | 1 |
| Baugé, E | 1 |
| Chinetti, G | 1 |
| Fruchart, J | 1 |
| Fruchart, JC | 1 |
| Dallongeville, J | 1 |
| Staels, B | 1 |
| Hahn, SE | 1 |
| Goldberg, DM | 1 |
12 other studies available for fenofibrate and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Lipoprotein profile and lipid metabolism of PXB-cells
Topics: Animals; Apolipoprotein B-100; Carcinoma, Hepatocellular; Cell Line, Tumor; Fenofibrate; Hep G2 Cell | 2020 |
Fenofibrate induces human hepatoma Hep3B cells apoptosis and necroptosis through inhibition of thioesterase domain of fatty acid synthase.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Fatty Acid Synthase, Type I; Fenofibrate; Hu | 2019 |
Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding | 2009 |
Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Feno | 2009 |
Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Fenofibra | 2010 |
Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fenofibrate; Ge | 2010 |
Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cycl | 2011 |
Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells.
Topics: Carcinoma, Hepatocellular; Cell Survival; Fenofibrate; Glycerol; Hep G2 Cells; Humans; Hydrophobic a | 2012 |
Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms.
Topics: Apoptosis; Calcium; Carcinoma, Hepatocellular; Cell Survival; Fenofibrate; Glutathione; Humans; Live | 2002 |
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
Topics: Biopsy; Carcinoma, Hepatocellular; Cell Line; DNA Primers; Fenofibrate; Gene Expression Regulation; | 2005 |
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; | 1999 |
Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate.
Topics: Apolipoproteins A; Apolipoproteins B; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cholesterol | 1992 |